X0306 4 2018-12-17 0 0001235007 ENDOCYTE INC ECYT 0001509415 Leamon Christopher P 3000 KENT AVE, SUITE A1-100 WEST LAFAYETTE IN 47906 0 1 0 0 Vice President of Research Common Stock 2018-12-17 4 M 0 20000 2.54 A 142482 D Common Stock 2018-12-17 4 M 0 26177 3.82 A 168659 D Common Stock 2018-12-17 4 M 0 13089 7.49 A 181748 D Common Stock 2018-12-17 4 M 0 22500 9.05 A 204248 D Common Stock 2018-12-17 4 M 0 20004 3.55 A 224252 D Common Stock 2018-12-17 4 M 0 2 5.10 A 224254 D Common Stock 2018-12-17 4 M 0 2 3.18 A 224256 D Stock Option (right to buy) 2.54 2018-12-17 4 M 0 20000 0 D 2019-03-05 Common Stock 20000 0 D Stock Option (right to buy) 3.82 2018-12-17 4 M 0 26177 0 D 2020-02-11 Common Stock 26177 0 D Stock option (right to buy) 7.49 2018-12-17 4 M 0 13089 0 D 2021-03-11 Common Stock 13089 0 D Stock Option (right to buy) 9.05 2018-12-17 4 M 0 22500 0 D 2021-04-14 Common Stock 22500 27500 D Stock option (right to buy) 3.55 2018-12-17 4 M 0 20004 0 D 2022-02-28 Common Stock 20004 59996 D Stock option (right to buy) 5.10 2018-12-17 4 M 0 2 0 D 2025-02-04 Common Stock 2 52498 D Stock option (right to buy) 3.18 2018-12-17 4 M 0 2 0 D 2026-02-04 Common Stock 2 52498 D Includes 263 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on December 14, 2018. The option is fully vested and immediately exercisable. Shares subject to this option vest 1/4 annually over a period of four years beginning February 4, 2017. /s/ Michael A. Sherman, Attorney-in-Fact for Christopher P. Leamon (power of attorney previously filed) 2018-12-19